croscarmellose sodium
Sponsors
University Medical Center Utrecht, Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting, Mggm LLC, Ospedale San Raffaele S.r.l., Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
Conditions
Acute myeloid leukemiaFamilial Adenomatous PolyposisMajor DepressionMonkeypoxMyelodysplastic syndromePatients with major depressive episode and moderate to severe insomnia disordernew-onset autoimmune type 1 diabetes
Phase 2
A phase 2b, single-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of oral Ladarixin in association with a single low dose of Antithymocyte Globulin in patients with new-onset autoimmune type 1 diabetes.
WithdrawnCTIS2025-524298-18-00
Target: 46Updated: 2026-04-09
A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)
Not yet recruitingCTIS2026-525282-50-00
Target: 15Updated: 2026-07-13
Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder - SM-1
CompletedCTIS2023-507399-27-00
Start: 2024-12-04End: 2025-01-31Target: 130Updated: 2024-11-19
HOVON 150 AML: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
Active, not recruitingCTIS2022-502832-37-00
Start: 2019-03-01Target: 852Updated: 2025-07-02
Phase 4
European Randomised Clinical Trial on mPOX Infection (EPOXI)
CompletedCTIS2022-501979-10-00
Start: 2024-08-08End: 2025-07-14Target: 335Updated: 2025-06-26
Efficacy and Safety of Daridorexant in Patients with Major Depressive Disorder (MDD) and Insomnia: Double-blind, randomized, controlled trial
Not yet recruitingCTIS2025-524794-16-00
Target: 134Updated: 2026-05-04